← SynDRA
BMS-852927
SynDRA canonical compound SYN0038658 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | NR1H2 |
|---|
| Mechanism of action | LXR agonist |
|---|
All known targets
Mechanisms of action (all sources)
- NR1H2 MODULATOR
- LXR-beta modulator
- NR1H3 MODULATOR
- LXR-alpha modulator
- NR1H2 AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- EXEL-04541041
- XL-041
- XL-652
- XCT-0179628
- XCT-628
- XL-652)
- LXR modulator, X-Ceptor Therapeutics
- LXR modulators, Exelixis/Sankyo
- Liver X receptormodulator, Exelixis/Sankyo
- Liver X receptor modulator, X-Ceptor
- LXR agonist (atherosclerosis), BMS/Exelixis
- LXR modulators, X-Ceptor Therapeutics/Sankyo
- Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo
- Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb
- H9649L8MZN
- RefChem:120751
- XL041
- UNII-H9649L8MZN
- MFCD31618069
- SCHEMBL779963
- C29H28Cl2F2N2O4S
- orb1707531
- GTPL14079
- HNAJDMYOTDNOBK-UHFFFAOYSA-N
- phenyl]imidazol-4-yl]propan-2-ol
- EX-A5105
- GAC91839
- BDBM50204072
- BMS852927
- BMS 852927 [WHO-DD]
- AKOS040741389
- CS-7926
- compound 15 [PMID: 27994765]
- DA-51252
- MS-30688
- HY-101973
- G16191
- T14679
- 6OX
Look up BMS-852927 in the interactive SynDRA portal →